Modulight Oyj on 30 March 2022, received a binding purchase order from one of the largest pharmaceutical companies in the world to deliver laser equipment and related services for a research project at its concept phase. The purchase order is related to a research project which the customer has started, and which strives to find new ways to treat lung cancer. Lung cancer is a common and fatal disease that causes the most cancer deaths in the world.

Laser-assisted therapy is one of the selected therapies to be studied and Modulight is the chosen partner for this particular treatment method. The ordered laser equipment is scheduled to be delivered during the third quarter of 2022, and the order includes supporting services for one year. The product is the cloud-connected Modulight ML7710 laser platform that can be flexibly used for a variety of medical purposes, including other customized and high value-added products.

The company's projects typically begin with a proof-of-concept phase of the concept and then progress to clinical trials and pilot production. If successful, the projects may eventually lead to commercialization, before which the customer must apply for regulatory approval for the application. The overall process from pilot production to a fully commercialized project typically takes several years and there is significant uncertainty associated with each step.

Modulight is currently on its silent period and will publish it's first quarter of 22 results on 28 March 2022.